Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · Real-Time Price · USD
176.73
-0.19 (-0.11%)
Nov 28, 2025, 4:00 PM EST - Market closed
Jazz Pharmaceuticals Employees
Jazz Pharmaceuticals had 2,800 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
2,800
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$1,484,940
Profits / Employee
-$131,601
Market Cap
10.74B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2,800 | 0 | - |
| Dec 31, 2023 | 2,800 | 0 | - |
| Dec 31, 2022 | 2,800 | -400 | -12.50% |
| Dec 31, 2021 | 3,200 | 1,260 | 64.95% |
| Dec 31, 2020 | 1,940 | 320 | 19.75% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
JAZZ News
- 9 days ago - Jazz Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference - PRNewsWire
- 10 days ago - Jazz Pharmaceuticals: Stock Soars On Zanidatamab Data - I'm Still On The Fence - Seeking Alpha
- 10 days ago - Jazz Pharmaceuticals' And Zymeworks' Ziihera Success: A Pleasant Surprise - Seeking Alpha
- 11 days ago - Zymeworks, Jazz Pharmaceuticals Stocks Climb On Robust Gastroesophageal Trial Outcomes And Upcoming Regulatory Plans - Benzinga
- 11 days ago - Jazz Pharmaceuticals and Zymeworks Report Positive Cancer Treatment Results. The Stocks Soar. - Barrons
- 11 days ago - Positive HERIZON-GEA-01 Phase 3 Results Support Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and Ziihera Combination Regimens as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinom - PRNewsWire
- 17 days ago - Jazz Pharmaceuticals Showcases New Clinical and Translational Data for Modeyso™ (dordaviprone) in H3 K27M-mutant Diffuse Midline Glioma at SNO 2025 - PRNewsWire
- 22 days ago - Jazz Pharmaceuticals plc (JAZZ) Q3 2025 Earnings Call Transcript - Seeking Alpha